<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163083</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1157-6624</org_study_id>
    <secondary_id>2013-609-f-S</secondary_id>
    <nct_id>NCT02163083</nct_id>
  </id_info>
  <brief_title>Detection of Lymphnodes Using ICG During RARP</brief_title>
  <official_title>Detection of Lymph Nodes by Means of Intraoperative Fluorescence Lymphography Using Indocyanine Green (ICG) During the Radical Robot-assisted Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital Gronau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital Gronau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate, whether the detection of lymph nodes by means of
      intraoperative fluorescence lymphography as part of lymphadenectomy in robot-assisted radical
      prostatectomy is higher than without the use of indocyanine green (ICG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ICG is a fluorescent dye that fluoresces green bound to proteins under illumination in the
      near-infrared range. Using this dye allows to visualize lymphatic nodes, by being injected
      into the tumor or directly surrounding tissue.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total number of detection rate of (positive) lymph nodes using ICG</measure>
    <time_frame>during the surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurements of the time, that takes to remove the lymph nodes</measure>
    <time_frame>During the surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the anatomical location of the ICG-positive lymph node</measure>
    <time_frame>During th surgery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Lymphadenectomy using standard Methods</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Lymphadenectomy will be performed as a standard procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphadenectomy using ICG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ICG</intervention_name>
    <description>Improvement of detection of positive lymphnodes</description>
    <arm_group_label>Lymphadenectomy using ICG</arm_group_label>
    <other_name>indocyanine green powder</other_name>
    <other_name>Pulsion Medical Systems, München, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed locally limited prostate cancer;

          -  Intermediate or high risk tumor

          -  Recommended and planned prostatectomy;

          -  Completed and signed written consent;

          -  Voluntarily agreement to participate in this study

          -  Age of the study participants ≥ 18 years.

        Exclusion Criteria:

          -  Allergic reaction to active ingredient (indocyanine green);

          -  Iodine allergy;

          -  Hyperthyroidism;

          -  High-grade renal impairment;

          -  High-grade hepatic insufficiency;

          -  Unwillingness to the storage and disclosure of pseudonymous disease and personal data

          -  psychiatric pre-existing conditions or other circumstances that make a cooperation by
             the patient in question
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörn H. Witt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital Gronau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius Hospital Gronau, Department for Urology, Pediatric Urology and Urologic Oncology</name>
      <address>
        <city>Gronau</city>
        <state>Moellenweg 22</state>
        <zip>48599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

